Capecitabine Tablet
Product Images NDC 55111-496

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 55111-496). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

Label for Capecitabine Tablets USP 150 mg oral tablets by Dr. Reddy's Laboratories Limited. The label states the drug is a cytotoxic agent, contains 60 tablets, and includes NDC 55111-496-60. It provides pharmacist instructions to dispense the accompanying patient package insert along with the medication.*

FDA Label Image

Container2 (Container2)

Capecitabine Tablets USP 500 mg oral tablets packaging label from Dr. Reddy's Laboratories Limited. The label states 120 tablets per container, notes the product as a cytotoxic agent, and includes instructions for pharmacists to dispense the accompanying patient package insert. National Drug Code (NDC) 55111-497-04 and barcode are visible. Storage instructions specify keeping the container tightly closed and storing at controlled room temperature.*

FDA Label Image

Figure1 (Figure1)

Chemical structure diagram showing the metabolic conversion pathway of capecitabine to its metabolites 5'-DFCR, 5'-DFUR, and 5-FU. The diagram includes enzymatic steps labeled as Carboxylesterase, Cyd deaminase, and dThdPase connecting the structures.*

FDA Label Image

Figure2 (Figure2)

A survival curve chart comparing two treatment groups: 5-FU + leucovorin and capecitabine over a period of 96 months since randomization. The y-axis represents survival probability, and the x-axis represents months. The graph includes data on the number of subjects at risk for each treatment group at various time points.*

FDA Label Image

Figure3 (Figure3)

A line graph depicting survival rates over months since randomization for two treatment groups: capecitabine and 5-FU + leucovorin. The y-axis represents survival probability, and the x-axis shows time in months. Two lines indicate survival trends for each group.*

FDA Label Image

Figure4 (Figure4)

A survival curve graph showing estimated probability over time (days) for two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittently. The x-axis represents time up to 1500 days, and the y-axis shows estimated probability from 0 to 1.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve showing estimated probability over time in days for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph includes arrows indicating median survival times for each group.*

FDA Label Image

Figure6 (Figure6)

A line graph comparing the estimated probability over time (in days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The graph shows survival or response probabilities declining over approximately 800 days, with distinct curves and annotated median time points.*

FDA Label Image

Structure (Structure)

Chemical structure of capecitabine, the active ingredient shown as a molecular diagram including atoms and bonds in a linear and cyclic arrangement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.